Home Blog Page 2

One-of-One Trail 70 Minibike Built by Hemmings Could Be Yours for Free

The “Hemmings Stay Gold Sweepstakes” gives one lucky winner a one-of-a-kind machine featuring metal flake artwork by renowned, custom artist Travis “Tuki” Hess

Hemmings, the original online collector car marketplace, today announced the launch of the “Hemmings Stay Gold Sweepstakes,” a giveaway offering one winner the opportunity to own a custom-built Trail 70 Minibike unlike any other.

Built from the ground up in the Hemmings Garage in Bennington, Vermont, the minibike, dubbed “Stay Gold,” is the product of countless hours from Shop Manager Junior Nevison, Technical Editor Terry McGean, and the Hemmings Garage team. The project began after the crew restored a family heirloom 1970 Honda CT-70 and rediscovered the charm of the minibike that introduced generations of enthusiasts to riding and wrenching. Inspired by the ability to source nearly every component new, the team set out to create something that honored the CT-70’s legacy while pushing its design in a new direction. Using all-new parts from Bart Moto Co., the Hemmings crew designed and assembled the custom machine before partnering with renowned painter Travis “Tuki” Hess, whose signature metal flake artwork gave Stay Gold its unmistakable personality. From concept to completion, Stay Gold showcases the dedication, craftsmanship, and countless hours invested by the Hemmings Garage team, as told in a video on Hemmings’ YouTube Channel. 

“Stay Gold represents everything we love about this hobby,” said Jonathan Shaw, President of Hemmings. “It’s creative, personal, and deeply rooted in the memories that first sparked our passion for cars and motorcycles. Projects like this remind us that collector culture today should preserve the past and balance that with inspiring the next generation of enthusiasts to build, create, and make memories of their own.” 

PHOTO EDITORS: Photos of the Hemmings Trail 70 Minibike are available at this link

To bring the vision to life, Hemmings partnered with Travis “Tuki” Hess of Kolor by Tuki Kustom Auto Paint. Widely respected throughout the drag racing and custom automotive communities, Hess is known for his intricate metal flake paintwork and period-inspired designs. For Stay Gold, he applied his signature artistry across the frame, fenders, and headlamp nacelle, creating a finish that captures the bold spirit of 1970s custom culture while remaining unmistakably original.

Every component was selected to complement the custom paint scheme and create a machine that feels equally at home on display or on the road. 

Features include:

  • 125cc engine with high-lift cam and manual four-speed gearbox
  • Nibbi 24mm carburetor
  • Wide-body frame with 5.5L fuel tank
  • Adjustable inverted aluminum front forks
  • One-piece aluminum 12-inch wheels
  • Coker Classic whitewall tires
  • Chrome drag-pipe exhaust
  • Hydraulic front disc brake and rear drum brake
  • Stretched aluminum swingarm
  • Digital speedometer cluster
  • Custom gold metal flake diamond-stitched seat hand-sewn by Hemmings Shop Manager Junior Nevison

380K produced, only one “Stay Gold”

According to the National Motorcycle Museum, the Honda CT-70 occupies a unique place in motorcycling history. Introduced in 1969 and sold through the early 1980s, the compact minibike helped introduce a generation of riders to motorcycling and became one of Honda’s most successful models, with more than 380,000 units produced. Its approachable size, distinctive styling, and enduring reliability made it a fixture in garages, campgrounds, and backyards across America, and it remains one of the most beloved minibikes among collectors today.

The custom “Stay Gold” CT-70 made its public debut on June 12, 2026 at the Paradise Road Show in Austin, Texas, and will appear at select events throughout the summer.

“Ask a hundred enthusiasts how they got started and many will point to a minibike, a project in the garage, or a machine that gave them their first taste of freedom,” said Dan Stoner, Creative Director at Hemmings. “Stay Gold taps into that feeling. It’s a reminder that some of the most meaningful vehicles aren’t the most expensive ones. They’re the ones that create lifelong memories.”

The “Stay Gold Sweepstakes” is now open and runs through August 20, 2026. One winner will take home the custom-built machine for free. While thousands of CT-70s have survived over the decades, there will only be one Hemmings “Stay Gold” minibike.

For complete rules and eligibility information, and to enter the sweepstakes, visit https://www.hmn.com/staygold. No purchase necessary. 

About Hemmings

Founded in 1954, Hemmings is the original online collector car marketplace. For more than 70 years, we have grown and uplifted the collector car community because we’ve been part of it since the start. Through our frictionless marketplace, quality entertainment, and professional service, we help all willing drivers buy, sell, and live the collector car lifestyle. Hemmings Motor Club extends this mission by bringing enthusiasts together through exclusive benefits, curated driving experiences, and deeper community connections for those who live to drive. More information, services, and content are available at https://www.hemmings.com/. Stay connected with Hemmings on Facebook, Instagram, and YouTube, and search tens of thousands of vehicle listings from the palm of your hand with the Hemmings App.

TrialAssure and Cancer Research UK Collaborate to Advance AI-Supported Regulatory Document Authoring

Cancer Research UK’s Centre for Drug Development is using TrialAssure LINK AI to support medical writing in CRUK-sponsored studies

TrialAssure, a leading technology provider advancing clinical trial transparency, disclosure, and data sharing, and Cancer Research UK’s Centre for Drug Development (CDD), today announce a new partnership to use TrialAssure LINK AI to support the development of regulatory and clinical trial documents for Cancer Research UK-sponsored studies.

The collaboration is focused on helping Cancer Research UK’s medical writing teams improve efficiency, reduce manual burden, and support the continued growth of the CDD’s portfolio of new cancer treatments. LINK AI is being used to assist with content generation across a range of clinical and regulatory document types, with human medical writing expertise remaining central for review, refinement, and finalization.

Cancer Research UK’s CDD began by assessing LINK AI for regulatory document authoring workflows. The team worked with TrialAssure to align out-of-the-box artificial intelligence (AI) configuration with internal templates and instructional text, and are reviewing AI-generated drafts as part of a structured human-in-the-loop process. Following initial work on the Investigator’s Brochure, Cancer Research UK will expand its assessment of LINK AI into additional document authoring workflows including Clinical Study Reports and patient narratives.

“Cancer Research UK’s Centre for Drug Development has a long history of advancing new treatments that have the potential to change outcomes for people affected by cancer,” said Prasad M. Koppolu, Chief Operating Officer at TrialAssure. “We are proud to support their medical writing teams with AI technology that is designed to increase efficiency, reduce repetitive work, and keep experienced professionals in control of the authoring process.”

For Cancer Research UK’s CDD, the initiative supports the responsible use of generative AI to improve regulatory authoring workflows and support authoring roles in keeping pace with a growing portfolio of new oncology studies.

“Cancer Research UK’s Centre for Drug Development has deep expertise in early-phase oncology, but our ambition to bring more innovative treatments to cancer patients requires more efficient ways of working. As our programmes grow in complexity – spanning combination agents, multi-region submissions and precision medicine platform trials – the volume of regulatory documents is placing increasing pressure on our teams,” said Amber Holmes, Head of Quality, Regulatory, Pharmacovigilance and Medical Writing at Cancer Research UK’s Centre for Drug Development.

“Partnering with TrialAssure allows us to explore how generative AI can streamline document authoring and free up our experts to focus on critical scientific content – helping CDD accelerate the delivery of cutting-edge treatments, including those targeting rare and hard-to-treat cancers. TrialAssure has worked closely with CDD to understand our needs, meet our rigorous requirements for technology solutions and establish a clear path for phased implementation of LINK AI,” added Holmes.

The collaboration demonstrates TrialAssure’s continued commitment to developing AI-enabled, human-driven solutions for regulated life sciences workflows. By pairing advanced content generation capabilities with medical writer oversight, LINK AI helps organizations introduce AI into medical writing processes in a responsible, practical, and scalable way.

“AI adoption in medical writing succeeds when the technology fits the way expert teams already work,” said Zach Weingarden, MS, Director, AI Technology & Applications at TrialAssure. “Our work with the incredible team at Cancer Research UK shows how organizations can use AI thoughtfully, starting with defined workflows, adapting prompts to existing templates, and giving medical writers the ability to review and shape every output.”

To learn more about TrialAssure LINK AI, visit: https://trialassure.com/software/linkai/

About Cancer Research UK’s Centre for Drug Development

Cancer Research UK has an impressive record of developing novel treatments for cancer. The Cancer Research UK Centre for Drug Development has been pioneering the development of new cancer treatments for 30 years. We have completed over 170 clinical trials designed to explore potential new anti-cancer agents in patients. Six of these new agents have made it to market, including temozolomide for brain cancer, abiraterone for prostate cancer and rucaparib for ovarian cancer. www.cruk.org.uk/cdd 

About TrialAssure

TrialAssure® is an award-winning global data transparency company providing fast, intelligent, and cost-effective software and services for the pharmaceutical industry and related sectors. A recognized leader in artificial intelligence (AI) and machine learning (ML), TrialAssure offers AI Enabled, Human Driven™ solutions that support compliance through document and data anonymization, AI-assisted content development, compliance tracking, and clinical trial disclosure. Founded in 2009, TrialAssure’s global team builds proven technology platforms that help Sponsors and research organizations stay aligned with transparency regulations worldwide. TrialAssure was named Data Solution of the Year by the Data Breakthrough Awards.

For more information, visit www.trialassure.com

SW North America to Showcase Live CNC Machining, Manufacturing Automation, and Cobot Demonstrations at IMTS 2026

SW North America, a leading supplier of horizontal multi- and single-spindle CNC machining centers, automation, and complete system solutions, announced today that it will bring an immersive manufacturing experience to IMTS 2026, taking place September 14–19, 2026, at McCormick Place in Chicago. Located at Booth #338250, SW North America will showcase live machining, collaborative robots, aerospace applications, CNC manufacturing automation, and interactive demonstrations designed to highlight the future of smart manufacturing.

Throughout the event, visitors will experience advanced CNC machining and manufacturing automation technologies operating together in real time. The booth experience is designed to show manufacturers how flexible machining systems and intelligent automation can help improve throughput, increase process reliability, and support evolving production requirements.

“IMTS gives manufacturers the opportunity to experience technology in action,” said Andrew Rowley, General Sales Manager, SW North America. “This year, we’re focused on demonstrating how CNC machining and manufacturing automation can work together to create smarter, more adaptable production environments across industries.”

Live Demo #1: BA 322 + Collaborative Robot + SW Souvenir Challenge Coins

One of the featured demonstrations will center around the SW BA 322 dual-table, dual-spindle CNC machining center paired with a collaborative robot, or cobot. During the live demonstration, the BA 322 will machine custom SW souvenir challenge coins while the cobot loads raw material and unloads finished components directly on the show floor.

Featured capabilities will include:

  • Dual-table, dual-spindle machining
  • Independent Z axes
  • Ball screw driven platform
  • Collaborative robot automation
  • Intelligent vision technology
  • Flexible automation integration

Unlike traditional industrial robots, the cobot is designed to safely operate alongside people using integrated sensing and intelligent motion technology. Visitors will also have the opportunity to select industry-themed challenge coins through an interactive game-show-style experience.

In addition to this demonstration, SW will showcase Digital Twin technology that creates a virtual representation of the BA 322 machining process. Visitors will see how manufacturers can simulate production scenarios, validate process changes, and optimize performance in a digital environment before implementing adjustments on the shop floor. The technology helps reduce risk, improve efficiency, and support smarter manufacturing decisions throughout the production lifecycle.

Live Demo #2: BA W06-22 Aerospace Blisk Machining

SW North America will feature live machining demonstrations using the BA W06-22 machining center producing an aerospace blisk component. The demonstration will showcase:

  • Aerospace CNC machining applications
  • Precision machining of complex geometries
  • Process reliability for critical aerospace components
  • High-performance material removal
  • Advanced balancing and pre-setter technology

A live pre-setter and balancing station will further demonstrate how aerospace manufacturers, and others that expect tight tolerances, can improve tooling accuracy and machining consistency for demanding production environments.

Live Demo #3: Zero-Point Fixture Change Technology

A third live demonstration will highlight zero-point fixture change technology using a cobot and automated fixture exchange platform. Designed for low-volume, high-mix production environments, the system demonstrates:

  • Faster fixture changeovers
  • Flexible manufacturing automation
  • Reduced downtime between production runs
  • Improved positioning accuracy
  • Greater manufacturing agility

In addition to live CNC machining and manufacturing automation demonstrations, booth visitors will also enjoy custom IMTS-themed t-shirts from SW, interactive automation technology displays, and live discussions with SW machining and automation experts.

Manufacturers attending IMTS 2026 are encouraged to add SW North America to their show plans and visit Booth #338250 firsthand. Details here: https://directory.imts.com/8_0/exhibitor/00066131/SW-North-America-Inc

For more information on SW North America’s CNC machining, manufacturing automation, and digital manufacturing solutions, visit https://sw-machines.com/us/.

About SW North America

SW North America is a subsidiary of Schwäbische Werkzeugmaschinen GmbH, a leading international manufacturer of smart manufacturing solutions. With its North American headquarters in Michigan, SW is the world market leader in multi-spindle CNC machining centers for cutting a variety of materials in the automotive, electromobility, agricultural and construction machinery, medical technology, and aerospace industries.

SW currently has more than 1,700 employees across its global headquarters in Schramberg-Waldmössingen, Germany, and locations in China, France, Hungary, Mexico, Poland, and the United States.

Learn more about SW North America at https://sw-machines.com/us/.

Dr. Oladayo Oyelola Joins TrialAssure’s Advisory Board to Support Clinical Trial Transparency Strategy 

Former Daiichi Sankyo transparency leader brings more than 30 years of experience across pharmaceutical research, clinical development, and global clinical trial disclosure

TrialAssure, a leading technology provider advancing clinical trial transparency, disclosure, and data sharing, today announced the appointment of Oladayo O. Oyelola, PhD, SC (ASCP), to its Advisory Leadership Team. In this role, Dr. Oyelola will support TrialAssure’s clinical trial transparency strategy and provide guidance on the continued advancement of solutions that help sponsors meet global disclosure, registration, results reporting, and data sharing requirements.

Dr. Oyelola brings more than 30 years of experience across pharmaceutical research, clinical development, regulatory operations, and global clinical trial transparency. He most recently served as Senior Director and Global Head of Clinical Trial Information Disclosure at Daiichi Sankyo, where he developed and led enterprise-wide strategy and operations supporting compliance with global transparency and data sharing requirements.

“Oladayo has built an extraordinary level of respect across the clinical trial transparency community through his leadership, depth of expertise, and commitment to responsible disclosure,” said Prasad M. Koppolu, Chief Operating Officer at TrialAssure. “His thought leadership has helped shape how organizations approach transparency strategy, operational readiness, and global compliance. We are honored to welcome him to TrialAssure’s Advisory Leadership Team as we continue helping the industry move transparency forward.”

Throughout his career, Oladayo has developed and implemented disclosure strategies aligned with EMA Policy 0070, Health Canada PRCI, Japan, China and other global mandates. His experience includes overseeing clinical trial registration, results disclosure, and data sharing activities across major portfolios, as well as building policies, processes, and training programs that support consistent and compliant global clinical trial disclosure operations.

His appointment comes as global transparency requirements continue to grow in scope and complexity, creating an increased need for strategic guidance, operational consistency, and technology-enabled approaches that help sponsors manage disclosure obligations across regions.

“During my time as a TrialAssure customer, I saw firsthand the company’s commitment to practical, responsible, and effective clinical trial transparency solutions,” said Dr. Oyelola. “I have long respected the team’s expertise and am pleased to join the Advisory Leadership Team to support its continued work helping sponsors strengthen disclosure strategy and global transparency operations.”

Oladayo’s expertise also spans medical and technical writing, regulatory submissions, and the development of enterprise-level training programs. His perspective will support TrialAssure as the company continues to advance its technology, services, and thought leadership across clinical trial transparency and disclosure.

“Oladayo understands clinical trial transparency from every angle, including the scientific, regulatory, and operational demands sponsors face,” said Koppolu. “That perspective will help guide our continued work to build practical solutions for global disclosure teams.”

To learn more about TrialAssure, visit www.trialassure.com.

ABOUT TRIALASSURE

TrialAssure® is an award-winning global data transparency company providing fast, intelligent, and cost-effective software and services for the pharmaceutical industry and related sectors. A recognized leader in artificial intelligence (AI) and machine learning (ML), TrialAssure offers AI Enabled, Human Driven™ solutions that support compliance through document and data anonymization, AI-assisted content development, compliance tracking, and clinical trial disclosure. Founded in 2009, TrialAssure’s global team builds proven technology platforms that help Sponsors and research organizations stay aligned with transparency regulations worldwide. TrialAssure was named Data Solution of the Year by the Data Breakthrough Awards.

For more information, visit www.trialassure.com

Kivo and CRISPR Therapeutics to Present 52-Day QMS Modernization at DIA 2026 in Philadelphia

Featured session explores how pharma, biotech, and CROs can rethink and modernize their QMS

Kivo, the unified document and process management system for life sciences teams, announced today that the company will co-present at the DIA Global Annual Meeting 2026 this June alongside CRISPR Therapeutics, whose aim is to find cures for people suffering from serious diseases through transformative gene-based medicines. The featured Kivo Innovation Theater session will spotlight how CRISPR Therapeutics switched to Kivo and modernized its Quality Management System (QMS) in just 52 days by simplifying processes and challenging traditional approaches to enterprise quality infrastructure.

The DIA session, titled “Nothing Changes Unless We Do – Implementing QMS with CRISPR Therapeutics in 52 Days,” will feature Kate Ellmer, Executive Director of Quality and PV Operations at CRISPR Therapeutics, alongside Chris Xistris, Vice President of Services at Kivo. Attendees will gain practical insight into how modern biotech organizations can rapidly implement scalable quality systems under compressed timelines without sacrificing compliance or operational agility.

“At CRISPR, one of our core company values is being entrepreneurial which encourages our employees to welcome change and creatively address the challenges we encounter as a small biotech,” said Ellmer. “As an industry, thinking entrepreneurially means we should always be considerate of our current needs while forecasting and developing plans for the successes we aspire to realize.”

The implementation marks a growing shift among scaling pharmaceutical and biotechnology companies, as well as clinical research organizations (CROs), that are moving away from rigid, hard-coded legacy platforms in favor of flexible systems designed for interoperability, scalability, and rapid deployment.

“Life science companies today are operating under enormous pressure to move quickly with lean teams and evolving infrastructure,” said Toban Zolman, CEO at Kivo. “The traditional model of drawn-out software implementations no longer aligns with how drug development can exist today. This work with CRISPR showed what becomes possible when teams simplify workflows and focus on the right things from day one.”

Kivo has seen particularly strong momentum among cell and gene therapy (CGT) and rare disease organizations, where lean operational teams often require scalable infrastructure without the complexity associated with traditional enterprise platforms.

During DIA, the Kivo Innovation Theater session will take place on June 15, 2026 from 1:05 PM to 1:35 PM at the Pennsylvania Convention Center (1101 Arch Street, Philadelphia, PA 19107 USA). Learn more about the session here, visit booth #1313 onsite, or request a meeting at https://kivo.io/.

About Kivo

Kivo is building the next generation of infrastructure for AI-driven drug development by partnering with life sciences teams to simplify Regulatory, Clinical, and Quality operations through a unified cloud platform. Designed for scaling pharmaceutical and biotech organizations, Kivo supports RIM, eTMF, QMS, controlled document management, submission assembly, eCTD lifecycle management, inspection readiness, SOP management, and training management within a single seamless environment. Unlike legacy vendors that rely on disconnected applications and lengthy implementations, Kivo offers compliant, audit-ready, continuous validation assurance – which avoids significant IT costs – both upfront and ongoing. With Part 11 compliant e-signatures, process automation, and modern cloud architecture, Kivo helps life sciences teams reduce operational friction across the drug development lifecycle.

For more information, visit: https://kivo.io/.

Troy Organic Ice Pop Brand Returns for its Third Summer at the Detroit Zoo and Makes Debut at Nick Gilbert Way

0

Lofty Pops, a Michigan-based handcrafted ice pop company, is returning to the Detroit Zoo for its third consecutive summer while making its debut at Nick Gilbert Way. The expansion marks another milestone for the company as it continues bringing organic, allergen-friendly frozen treats to community spaces across the region. 

Following a successful launch at the Detroit Zoo, Lofty Pops quickly became a standout favorite among families looking for cleaner, allergen-friendly frozen treats. What began as a local partnership has helped propel the Michigan-based brand into five Midwest zoos heading into summer 2026, marking a period of strong growth for the company.

This summer Lofty Pops is also opening at Nick Gilbert Way, a new public plaza connecting Woodward Avenue to Farmer Street between the Hudson’s Detroit building and tower, placing Lofty Pops along Lower Woodward, the city’s busiest entertainment and cultural corridor. As part of summertime programming in partnership with Bedrock, Lofty Pops will join other local vendors at the plaza on Thursdays and Fridays from 4 to 9 p.m., Saturdays from noon to 9 p.m. and Sundays from noon to 6 p.m. With major events like Movement Festival, Grand Prix and Ford Fireworks drawing thousands downtown, the location represents another significant milestone as Lofty Pops continues expanding across high-traffic destinations throughout the Midwest.

“We keep hearing from families that Lofty Pops has become their favorite go-to summer treat and that means everything to us,” said Natalie Heiter, co-founder of Lofty Pops. “Detroiters have embraced us from the beginning, so having these iconic destinations support us this summer is an honor we’re truly humbled by.”

For Detroit families, the expansion means access to something that has historically been hard to find downtown: a frozen treat that works for people with dietary restrictions. Every Lofty Pop is dairy-free, gluten-free and allergen-friendly, chef-crafted with real fruit and certified organic ingredients, and free from artificial colors and flavors. The packaging is completely plastic-free and home compostable.

This season’s lineup includes Strawberry Lemon, Orange Dreamsicle, Piña Colada, Blue Razzberry and Chocolate Fudge, among other rotating flavors. 

Heiter added, “My brother and I were raised by entrepreneurial parents, and that mindset shaped how we’ve built Lofty Pops from the beginning. We’ve stayed hands-on, authentic, and deeply connected to the communities around us. As a southeastern Michigan company, seeing major destinations in our own backyard believe in what we’re building while we continue expanding nationally means so much.” 

Lofty Pops is expanding to five Midwest zoos this summer and has additional regional and retail partnerships planned for the 2026 season. More information is available at loftypops.com/locations

About Lofty Pops

Lofty Pops is a handcrafted ice pop brand founded by a brother and sister team dedicated to creating better-for-you frozen treats. Each flavor is chef-crafted using real fruit and certified organic ingredients, with no artificial colors or flavors. Lofty Pops are dairy-free, gluten-free and allergen-friendly, making them accessible to families with diverse dietary needs. Since launching in 2024, Lofty Pops has expanded to premier family destinations across the Midwest and is continuing its national growth in 2026. For more information, visit loftypops.com or follow @eatloftypops on social media.

Kivo Expands Life Sciences Leadership Team with Appointment of Former Veeva Executive Chris Xistris

Kivo, the unified document and process management system for life sciences teams, announced today that Chris Xistris has joined the company as Vice President of Services.

Xistris brings more than 25 years of experience across Regulatory Operations, Clinical Operations, Quality systems, and enterprise software transformation. Prior to joining Kivo, he spent more than a decade at Veeva Systems, where he most recently served as Senior Director, R&D Services Engagement. During his tenure, he led adoption and transition planning efforts across more than 600 customer engagements spanning Regulatory, Clinical, Quality, Commercial, and Safety domains.

At Kivo, Xistris now oversees the continued expansion and scaling of the company’s Services organization as demand grows among pharmaceutical, biotech, and clinical research organizations (CROs) seeking modern, interoperable alternatives to legacy enterprise systems.

“Chris understands the issues that firms in our industry face because he has experienced them from every angle, including sponsor operations, consulting, and enterprise SaaS transformation,” said Toban Zolman, CEO at Kivo. “He has helped hundreds of organizations navigate complex operational and technology transitions throughout his career. That perspective is incredibly valuable as AI reshapes drug development and companies search for faster, more connected ways to work.”

Xistris began his career working directly within Regulatory and Clinical Operations teams at small and mid-sized biotech organizations, where he focused on TMF management, investigational drug submission management, and the implementation of content and information management systems. He later transitioned into consulting, helping organizations build and scale regulatory operations infrastructure, improve business processes, and modernize operational workflows.

“Kivo represents the kind of nimble, forward-thinking company that I’ve wanted to be part of for a long time,” said Xistris. “The industry is entering a major period of change driven by AI and the need for faster, more connected operations. Kivo understands where drug development is headed and has built a platform around that reality. I’m incredibly excited to join a team that is helping modern biotech organizations scale with greater speed and flexibility.”

Kivo continues to see growing momentum across the life sciences industry, and through its expanding partner ecosystem, Kivo is helping organizations standardize workflows, simplify collaboration, accelerate implementation timelines, and maintain audit-ready compliance across sponsor projects and internal operations. Additionally, the company recently announced Kivo Headless GxP™, a new open architecture designed to help life sciences organizations operationalize agentic AI across Regulatory, Clinical, and Quality workflows.

To meet Chris in-person, see him at the DIA Global Annual Meeting in Philadelphia at booth #1313, or register for the Kivo Headless GxP debut event on June 8th at 10am PT at kivo.io/webinar/headless-launch.

About Kivo

Kivo is building the next generation of infrastructure for AI-driven drug development by partnering with life sciences teams to simplify Regulatory, Clinical, and Quality operations through a unified cloud platform. Designed for scaling pharmaceutical and biotech organizations, Kivo supports RIM, eTMF, QMS, controlled document management, submission assembly, eCTD lifecycle management, inspection readiness, SOP management, and training management within a single seamless environment. Unlike legacy vendors that rely on disconnected applications and lengthy implementations, Kivo offers compliant, audit ready, continuous validation assurance – which avoids significant IT costs – both upfront and ongoing. With Part 11 compliant e-signatures, process automation, and modern cloud architecture, Kivo helps life sciences teams reduce operational friction across the drug development lifecycle.

For more information, visit: https://kivo.io/.

PumasAI Launches New Enterprise AI Transformation Service That is Proven to Help Pharmaceutical Teams Achieve 50% Productivity Growth

New offering helps pharmaceutical and biotech organizations modernize pharmacometrics workflows, reduce manual work, and accelerate drug development timelines

DOVER, DEL. (May 21, 2026) — PumasAI, an AI-powered clinical pharmacology and pharmacometrics company transforming how pharmaceutical teams work, today announced the launch of Catalyst, a new enterprise  AI transformation service built to help pharmaceutical and biotech organizations achieve up to 50 percent productivity growth within 12 months through smarter AI adoption, workflow modernization, and stronger operational alignment.

After implementing artificial intelligence powered workflows and automation across its internal consulting teams, PumasAI dramatically reduced time spent on repetitive tasks, accelerated modeling workflows, and created more capacity for scientists to focus on higher-value scientific decision-making. The company is now bringing that same transformation model to pharmaceutical and biotech organizations looking to modernize their own operations and bring therapies to market faster.

“Catalyst started with our own team to prove the concept,” said Dr. Vijay Ivaturi, Co-Founder and CEO of PumasAI. “We saw firsthand what happens when AI is thoughtfully embedded into scientific workflows. Our teams became faster, more efficient, with better quality, and better positioned to focus on scientific rigor instead of repetitive operational tasks. After seeing a 50 percent productivity increase ourselves, and on a journey towards higher numbers, we knew we had to help other organizations achieve the same outcome.”

Overcoming clinical pharmacology and pharmacometrics challenges

Catalyst addresses several longstanding challenges that continue to slow clinical pharmacology and pharmacometrics teams across the pharmaceutical industry, such as:

  • MIDD workflows and analyses often require weeks of manual coding, diagnostic reviews, and repeated iterations.
  • Legacy platforms often require highly specialized expertise while limiting speed and automation opportunities.
  • Many teams remain stuck in fragmented workflows across multiple software, creating unnecessary handoffs that slow execution and increase the risk of errors.

As regulatory demands continue to increase, clinical pharmacology and pharmacometrics teams are asked to do more, and many scientists spend too much time managing workflows instead of driving scientific strategy.

PumasAI’s Enterprise AI Transformation service helps organizations solve those challenges by modernizing workflows through Pumas, PumasAide, and enterprise-approved AI tools. Organizations can expect the following proven outcomes from Catalyst:

  • Up to 50 percent overall productivity growth within 12 months.
  • Reduced time spent on repetitive workflow tasks.
  • Approximately twice as many model variants explored during each analysis.
  • Faster progression from raw data to regulatory-ready reports.

New, simple AI engagement model

Catalyst is delivered through a three-phase engagement model designed to create measurable progress for clinical pharmacology and pharmacometrics teams at every step, as follows:

  • Discover: PumasAI conducts workflow mapping, tool-chain audits, infrastructure reviews, team assessments, and productivity benchmarking to identify inefficiencies and deliver a prioritized roadmap.
  • Transform: Teams migrate existing model libraries into Pumas, deploy PumasAide, replace manual workflows with automated pipelines, and implement validation frameworks aligned with internal requirements. Organizations can target a 25 to 30 percent productivity improvement during this phase.
  • Accelerate: PumasAI supports full team certification, safe parallel-run transitions for critical analyses, targeted optimization efforts, and long-term sustainability planning designed to help organizations reach and maintain a 50 percent productivity goal.

Throughout the engagement, PumasAide helps scientists streamline daily work by assisting with scientific model code generation and data preparation, automating diagnostics and sensitivity analyses, drafting regulatory documentation, and orchestrating end-to-end workflows with intelligent checkpoints. Every output remains reviewed and approved by clinical pharmacology and pharmacometrics scientists to ensure teams remain fully in control.

“We believe the future belongs to scientific teams that can combine human expertise with intelligent automation,” added Ivaturi. “The organizations that make this shift now will move faster, learn faster, and ultimately bring better therapies to patients sooner.”

For more information about Catalyst, PumasAI’s Enterprise AI Transformation service, visit https://pumas.ai/our-services/ai-task-force

Or, register to join PumasAI for its latest webinar on In-Silico Clinical Trials with NLME Models, here: https://pumas.ai/events/in-silico-clinical-trials-with-nlme-models.

About PumasAI

PumasAI is an award-winning, AI-powered clinical pharmacology and pharmacometrics company transforming how pharmaceutical teams work. Proprietary software and AI tools developed by the company includes the Pumas suite of products, an integrated modeling and simulation platform designed to multiply productivity across the drug development lifecycle. Scientists at PumasAI provide consulting with leading pharmaceutical innovators in clinical pharmacology, model-informed drug development (MIDD), pharmacometrics, front-end applications, and more.

For additional information, visit www.pumas.ai

Hemmings Launches Max Bid, Letting Buyers Bid Smarter on Collector Cars

0

New automatic-bidding feature gives buyers confidence and budget control without requiring them to monitor auctions in real time

Hemmings Auctions has introduced Max Bid, a new buyer’s tool on Hemmings.com designed to make collector-car buying easier, smarter, and far less stressful. The automatic bidding tool allows buyers to set a spending limit and let the platform handle the bidding on their behalf, giving collectors greater confidence and control without requiring them to monitor auctions in real time.

With Max Bid, participants enter the highest price they are willing to pay before or during an active auction. From there, the Hemmings system places bids automatically in standard increments, responding to competing offers until the auction ends or the buyer’s preset ceiling is reached. If the buyer wins, they pay only the lowest amount necessary to secure the vehicle, not their full maximum.

“Max Bid is designed to give buyers confidence, convenience, and control, while preserving fair, transparent auction dynamics,” said Hemmings President Jonathan Shaw. “Our goal is to simplify the buying experience for collectors as they seek out that perfect vehicle they’d love to own.”  

The feature is designed specifically for the realities of the collector-car market, where auctions often attract bidders across multiple time zones and last-minute activity can determine the outcome. By removing the pressure of being online when the auction closes, Max Bid gives collectors a more flexible, convenient way to participate.

Secure Bidding

Collectors may enter a Max Bid at any point during an open auction. The amount remains completely private, with competing buyers seeing only the current high bid, not the maximum another bidder has set. To ensure clean and transparent bidding mechanics, the system prevents two participants from submitting identical maximum bids, eliminating the possibility of tied proxy offers. 

There are no additional fees, and standard auction rules and bid increments remain unchanged. Multiple buyers can place Max Bids on the same vehicle, provided each maximum amount is unique.

Built for Busy Collectors

Hemmings developed Max Bid in response to common challenges that often prevent buyers from securing the vehicles they want. Conflicting schedules, time-zone differences, and the temptation to overspend in the heat of a fast-moving auction can all work against collectors.

Max Bid addresses these issues with a true “set-it-and-forget-it” approach. Buyers can commit to a price they feel comfortable with, then step away knowing the system will continue to bid on their behalf. Whether an auction closes during work hours, overnight, or while a buyer is traveling or attending a car show, Max Bid remains active, competing up to the chosen limit.

Why Max Bid Matters for Sellers

For sellers, Max Bid helps drive stronger, more competitive auctions by keeping serious buyers engaged through the final moments. By allowing collectors to commit to their true maximum price — without worrying about timing or missing the close — bidding becomes deeper and more consistent, often resulting in more complete market value. The feature also broadens participation across time zones, bringing more qualified bidders into play and giving sellers greater confidence that their vehicle is competing in a fair, active, and fully engaged auction environment.

Part of a Broader Buying Experience

Max Bid is part of a growing suite of buyer and seller focused tools available on Hemmings.com. The platform also offers Pay + Title, a streamlined post-sale transaction service; Hemmings Motor Club membership benefits; Valuations for market-based pricing insights; and Price Guidance to help buyers understand a vehicle’s true market value before bidding.

Together, these tools aim to simplify every stage of the collector’s journey, from research and valuation to bidding, payment, title transfer, insurance and shipping.

AvailabilityMax Bid is available now to all registered users on Hemmings.com. No additional sign-up or fees are required beyond a standard Hemmings account.

Lofty Pops Expands Presence at Brookfield Zoo Chicago, Bringing Better-for-You Frozen Treats to Chicagoland Families

0

Handcrafted ice pop brand returns for second season with expanded footprint


Lofty Pops, a handcrafted ice pop company, is now available at Brookfield Zoo Chicago for the 2026 season with an expanded presence, building on a successful partnership in 2025 with SSA Group—the Zoo’s official concession and retail provider. Lofty Pops now offers guests even greater access through a dedicated kiosk and a mobile cart.

Lofty Pops are chef-developed and handcrafted with real fruit and organic ingredients, free from artificial colors and flavors. Each pop is dairy-free, gluten-free and allergen-friendly, with completely plastic-free, home compostable packaging—supporting Brookfield Zoo Chicago’s sustainability efforts while offering families a premium frozen treat option that meets growing demand for clean-label concessions.

“Our goal is to modernize frozen concessions by delivering a product that reflects how families eat today,” said Natalie Heiter, co-founder and chief marketing officer of Lofty Pops. “We’re thrilled to build on the momentum from our first year at Brookfield Zoo Chicago by expanding our presence this season and making Lofty Pops even more accessible to families visiting the Zoo.”

Brookfield Zoo Chicago guests can find Lofty Pops at the North Gate Market, South Gate Market and Coast Gifts. The kiosk is located outside Graze Kitchen near The Living Coast and a mobile cart will be positioned outside during special events.


As one of the largest metropolitan areas in the Midwest, Chicagoland continues to see rising demand for better-for-you food options, particularly in high-traffic family venues. Lofty Pops’ expansion into this market reflects a broader shift toward cleaner ingredients and more inclusive offerings that cater to a wide range of dietary needs.

Lofty Pops offers a rotating lineup of fruit-forward flavors, including Strawberry Lemon, Watermelon Bliss, Orange Dreamsicle, Dino Pop and more.

As Lofty Pops continues to expand, the company is focused on strategic growth across zoos, amusement venues and regional attractions, with plans for continued Midwest expansion in 2026.

Get a taste of Lofty Pops this summer at Brookfield Zoo Chicago located at 8400 31st Street, Brookfield, IL 60513. Visit www.loftypops.com to learn more.About Lofty Pops
Lofty Pops is a handcrafted ice pop brand founded by a brother-and-sister team dedicated to creating better-for-you frozen treats. Each flavor is chef-crafted using real fruit and certified organic ingredients, with no artificial colors or flavors. Lofty Pops are dairy-free, gluten-free and allergen-friendly, making them accessible to families with diverse dietary needs. Since launching in 2024, Lofty Pops has expanded to premier family destinations across the Midwest and is continuing its national growth in 2026. For more information, visit https://www.loftypops.com or follow @eatloftypops on social media.